Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092164039> ?p ?o ?g. }
- W3092164039 endingPage "490" @default.
- W3092164039 startingPage "481" @default.
- W3092164039 abstract "<b><i>Background:</i></b> Immune checkpoint inhibitors (ICI) have changed therapy strategies for cancer patients tremendously. Some approved ICI acquire testing of PD-L1 expression on tumor and/or immune cells. However, since PD-L1 testing is a comprehensive issue with various assays, antibody clones, scoring methods, and cut-offs, we aimed to summarize the recommendations and technical and histopathological issues of diagnostic PD-L1 assessment with an emphasis on invasive breast cancer (IBC). <b><i>Summary:</i></b> Besides other (pre)analytical considerations, selecting the most adequate PD-L1 immunohistochemical assay/antibody clone is important. In-house assay validation, prediagnostic training, and internal and external quality assurance should be implemented. The current most relevant PD-L1 assays and scores will be explained in this review. Moreover, recommendations for PD-L1 testing in IBC are outlined. <b><i>Key Messages:</i></b> Atezolizumab plus nab-paclitaxel therapy is approved for adult patients with locally advanced or metastatic triple negative breast cancer (mTNBC), if the tumor-associated immune cells express PD-L1. – This PD-L1 immune cell positivity is defined as an immune cell (IC) score, which refers to the area occupied by PD-L1 positive immune cells (lymphocytes, dendritic cells, macrophages, and granulocytes) as a percentage of the whole tumor area. The cut-off is an IC score ≥1%. In the approval study for atezolizumab in mTNBC, IC score was assessed using the Ventana PD-L1 SP142 assay. Other assays or laboratory developed tests may be used depending on country-specific drug approvals. However, harmonization studies have to show whether other PD-L1 tests are reliable and of clinical value to predict the response of breast cancer patients to ICI." @default.
- W3092164039 created "2020-10-15" @default.
- W3092164039 creator A5049585448 @default.
- W3092164039 creator A5089383800 @default.
- W3092164039 date "2020-01-01" @default.
- W3092164039 modified "2023-10-14" @default.
- W3092164039 title "Understanding PD-L1 Testing in Breast Cancer: A Practical Approach" @default.
- W3092164039 cites W2044702943 @default.
- W3092164039 cites W2066671159 @default.
- W3092164039 cites W2097255042 @default.
- W3092164039 cites W2117692326 @default.
- W3092164039 cites W2118272646 @default.
- W3092164039 cites W2131994307 @default.
- W3092164039 cites W2132619562 @default.
- W3092164039 cites W2136859769 @default.
- W3092164039 cites W2156353875 @default.
- W3092164039 cites W2198093519 @default.
- W3092164039 cites W2259802687 @default.
- W3092164039 cites W2401835169 @default.
- W3092164039 cites W2467854262 @default.
- W3092164039 cites W2557730509 @default.
- W3092164039 cites W2560367415 @default.
- W3092164039 cites W2572174216 @default.
- W3092164039 cites W2781879617 @default.
- W3092164039 cites W2794306956 @default.
- W3092164039 cites W2806074020 @default.
- W3092164039 cites W2809032787 @default.
- W3092164039 cites W2889746019 @default.
- W3092164039 cites W2896913521 @default.
- W3092164039 cites W2897422388 @default.
- W3092164039 cites W2900997972 @default.
- W3092164039 cites W2946550606 @default.
- W3092164039 cites W2953463746 @default.
- W3092164039 cites W2966340800 @default.
- W3092164039 cites W2978475373 @default.
- W3092164039 cites W2982176189 @default.
- W3092164039 cites W2989713744 @default.
- W3092164039 cites W2990398119 @default.
- W3092164039 cites W2999400187 @default.
- W3092164039 cites W3006930853 @default.
- W3092164039 cites W3010122169 @default.
- W3092164039 doi "https://doi.org/10.1159/000510812" @default.
- W3092164039 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7650134" @default.
- W3092164039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33223991" @default.
- W3092164039 hasPublicationYear "2020" @default.
- W3092164039 type Work @default.
- W3092164039 sameAs 3092164039 @default.
- W3092164039 citedByCount "28" @default.
- W3092164039 countsByYear W30921640392021 @default.
- W3092164039 countsByYear W30921640392022 @default.
- W3092164039 countsByYear W30921640392023 @default.
- W3092164039 crossrefType "journal-article" @default.
- W3092164039 hasAuthorship W3092164039A5049585448 @default.
- W3092164039 hasAuthorship W3092164039A5089383800 @default.
- W3092164039 hasBestOaLocation W30921640391 @default.
- W3092164039 hasConcept C121608353 @default.
- W3092164039 hasConcept C126322002 @default.
- W3092164039 hasConcept C143998085 @default.
- W3092164039 hasConcept C159654299 @default.
- W3092164039 hasConcept C203014093 @default.
- W3092164039 hasConcept C2775949291 @default.
- W3092164039 hasConcept C2777292972 @default.
- W3092164039 hasConcept C2777701055 @default.
- W3092164039 hasConcept C2780057760 @default.
- W3092164039 hasConcept C2780110267 @default.
- W3092164039 hasConcept C2781053074 @default.
- W3092164039 hasConcept C502942594 @default.
- W3092164039 hasConcept C530470458 @default.
- W3092164039 hasConcept C71924100 @default.
- W3092164039 hasConcept C8891405 @default.
- W3092164039 hasConceptScore W3092164039C121608353 @default.
- W3092164039 hasConceptScore W3092164039C126322002 @default.
- W3092164039 hasConceptScore W3092164039C143998085 @default.
- W3092164039 hasConceptScore W3092164039C159654299 @default.
- W3092164039 hasConceptScore W3092164039C203014093 @default.
- W3092164039 hasConceptScore W3092164039C2775949291 @default.
- W3092164039 hasConceptScore W3092164039C2777292972 @default.
- W3092164039 hasConceptScore W3092164039C2777701055 @default.
- W3092164039 hasConceptScore W3092164039C2780057760 @default.
- W3092164039 hasConceptScore W3092164039C2780110267 @default.
- W3092164039 hasConceptScore W3092164039C2781053074 @default.
- W3092164039 hasConceptScore W3092164039C502942594 @default.
- W3092164039 hasConceptScore W3092164039C530470458 @default.
- W3092164039 hasConceptScore W3092164039C71924100 @default.
- W3092164039 hasConceptScore W3092164039C8891405 @default.
- W3092164039 hasIssue "5" @default.
- W3092164039 hasLocation W30921640391 @default.
- W3092164039 hasLocation W30921640392 @default.
- W3092164039 hasLocation W30921640393 @default.
- W3092164039 hasLocation W30921640394 @default.
- W3092164039 hasOpenAccess W3092164039 @default.
- W3092164039 hasPrimaryLocation W30921640391 @default.
- W3092164039 hasRelatedWork W2473036963 @default.
- W3092164039 hasRelatedWork W2785808209 @default.
- W3092164039 hasRelatedWork W2903848939 @default.
- W3092164039 hasRelatedWork W2969038597 @default.
- W3092164039 hasRelatedWork W2979692290 @default.
- W3092164039 hasRelatedWork W3138330343 @default.